
Barnaby Young

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7664847/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA - Journal of the American Medical Association, 2020, 323, 1488.	3.8	1,700
2	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nature Biotechnology, 2020, 38, 1073-1078.	9.4	1,042
3	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	2.9	568
4	Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet, The, 2020, 395, 1039-1046.	6.3	561
5	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	3.8	538
6	Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet, The, 2020, 396, 603-611.	6.3	394
7	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	3.4	322
8	Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. Ophthalmology, 2020, 127, 977-979.	2.5	317
9	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	2.8	231
10	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. Clinical Infectious Diseases, 2020, 71, 2199-2206.	2.9	227
11	Hybrid metagenomic assembly enables high-resolution analysis of resistance determinants and mobile elements in human microbiomes. Nature Biotechnology, 2019, 37, 937-944.	9.4	216
12	Epidemiological and Clinical Predictors of COVID-19. Clinical Infectious Diseases, 2020, 71, 786-792.	2.9	181
13	Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. JAMA - Journal of the American Medical Association, 2020, 323, 527.	3.8	169
14	Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. New England Journal of Medicine, 2021, 385, 1401-1406.	13.9	161
15	Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet, The, 2014, 383, 1474-1482.	6.3	144
16	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	2.9	143
17	Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nature Communications, 2020, 11, 5243.	5.8	138
18	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	2.7	120

#	Article	IF	CITATIONS
19	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 2021, 10, .	2.8	113
20	SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. New England Journal of Medicine, 2020, 382, 1476-1478.	13.9	111
21	Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. Journal of Infectious Diseases, 2018, 217, 731-741.	1.9	105
22	Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infectious Diseases, The, 2015, 15, 793-802.	4.6	104
23	Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergencyAcesarean delivery, differential diagnosisÂinÂtheÂacutely ill parturient, care of the newborn,Aand protection of the healthcare personnel. American Journal of Obstetrics and Gynecology, 2020, 223, 66-74.e3.	0.7	104
24	Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut. Nature Ecology and Evolution, 2020, 4, 1256-1267.	3.4	98
25	COVID-19 in gastroenterology: a clinical perspective. Gut, 2020, 69, 1144-1145.	6.1	96
26	Statin use is associated with lower disease severity in COVID-19 infection. Scientific Reports, 2020, 10, 17458.	1.6	93
27	The place for remdesivir in COVID-19 treatment. Lancet Infectious Diseases, The, 2021, 21, 20-21.	4.6	91
28	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerging Microbes and Infections, 2020, 9, 900-902.	3.0	89
29	Serological differentiation between COVID-19 and SARS infections. Emerging Microbes and Infections, 2020, 9, 1497-1505.	3.0	89
30	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	3.9	89
31	Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine, 2017, 35, 212-221.	1.7	78
32	Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105549.	0.7	77
33	Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofab156.	0.4	77
34	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE, 2021, 16, e0253487.	1.1	76
35	Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore. Clinical Infectious Diseases, 2017, 64, S68-S75.	2.9	62
36	The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e48-e51.	1.4	61

#	Article	IF	CITATIONS
37	Absence of contamination of personal protective equipment (PPE) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection Control and Hospital Epidemiology, 2020, 41, 614-616.	1.0	59
38	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Journal of Experimental Medicine, 2022, 219, .	4.2	59
39	Testing for SARS-CoV-2: Can We Stop at 2?. Clinical Infectious Diseases, 2020, 71, 2246-2248.	2.9	52
40	Nonconcordance with Surgical Site Infection Prevention Guidelines and Rates of Surgical Site Infections for General Surgical, Neurological, and Orthopedic Procedures. Antimicrobial Agents and Chemotherapy, 2011, 55, 4659-4663.	1.4	50
41	COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 663-674.	1.0	49
42	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i> , <i>Morganella morganii</i> , <i>Providencia</i> spp, or <i>Serratia marcescens</i> : A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 2021, 8, ofab387.	0.4	42
43	Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the longâ€term outcomes in <scp>COVID</scp> â€19 patients. American Journal of Hematology, 2022, 97, 915-923.	2.0	42
44	Blood and blood product use during <scp>COVID</scp> â€19 infection. American Journal of Hematology, 2020, 95, E158-E160.	2.0	41
45	A prospective observational study of the prevalence and risk factors for colonization by antibiotic resistant bacteria in patients at admission to hospital in Singapore. BMC Infectious Diseases, 2014, 14, 298.	1.3	39
46	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Reports Medicine, 2021, 2, 100193.	3.3	37
47	Clinical utility of chest radiography for severe COVID-19. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1540-1550.	1.1	36
48	Asymptomatic COVIDâ€19: disease tolerance with efficient antiâ€viral immunity against SARSâ€CoVâ€2. EMBO Molecular Medicine, 2021, 13, e14045.	3.3	36
49	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa375.	0.4	33
50	Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS oVâ€2) infection. Clinical and Translational Immunology, 2020, 9, e1160.	1.7	31
51	Reversible platypnea-orthodeoxia in COVID-19 acute respiratory distress syndrome survivors. Respiratory Physiology and Neurobiology, 2020, 282, 103515.	0.7	30
52	Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. Lancet Infectious Diseases, The, 2021, 21, 1195-1197.	4.6	29
53	Predictors for development of critical illness amongst older adults with COVID-19: Beyond age to age-associated factors. Archives of Gerontology and Geriatrics, 2021, 94, 104331.	1.4	27
54	Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study. Nephron, 2021, 145, 256-264.	0.9	27

#	Article	IF	CITATIONS
55	Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority Study. Clinical Infectious Diseases, 2020, 71, 952-959.	2.9	26
56	Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology. Human Vaccines and Immunotherapeutics, 2020, 16, 1659-1667.	1.4	22
57	Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific, 2021, 15, 100276.	1.3	22
58	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine, 2021, 66, 103319.	2.7	21
59	Safety and potential efficacy of cyclooxygenaseâ€2 inhibitors in coronavirus disease 2019. Clinical and Translational Immunology, 2020, 9, e1159.	1.7	19
60	Human neutralising antibodies elicited by SARSâ€CoVâ€2 nonâ€D614G variants offer crossâ€protection against the SARSâ€CoVâ€2 D614G variant. Clinical and Translational Immunology, 2021, 10, e1241.	1.7	18
61	Epidemiology and Relative Severity of Influenza Subtypes in Singapore in the Post-Pandemic Period from 2009 to 2010. Clinical Infectious Diseases, 2017, 65, 1905-1913.	2.9	17
62	Diagnostic performance of COVIDâ€19 serological assays during early infection: A systematic review and metaâ€analysis of 11Â516 samples. Influenza and Other Respiratory Viruses, 2021, 15, 529-538.	1.5	17
63	Clinical course and physiotherapy intervention in 9 patients with COVID-19. Physiotherapy, 2020, 109, 1-3.	0.2	16
64	Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Scientific Reports, 2021, 11, 7477.	1.6	16
65	The avian influenza vaccine Emerflu. Why did it fail?. Expert Review of Vaccines, 2015, 14, 1125-1134.	2.0	15
66	Differentiating coronavirus disease 2019 (COVID-19) from influenza and dengue. Scientific Reports, 2021, 11, 19713.	1.6	15
67	Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection. Journal of Clinical Immunology, 2022, 42, 214-229.	2.0	15
68	Pregnancy Outcomes in COVID-19: A Prospective Cohort Study in Singapore. Annals of the Academy of Medicine, Singapore, 2020, 49, 857-869.	0.2	15
69	Semiannual Versus Annual Influenza Vaccination in Older Adults in the Tropics: An Observer-blind, Active-comparator–controlled, Randomized Superiority Trial. Clinical Infectious Diseases, 2019, 69, 121-129.	2.9	14
70	Acute Onset of Bilateral Follicular Conjunctivitis in two Patients with Confirmed SARS-CoV-2 Infections. Ocular Immunology and Inflammation, 2020, 28, 1280-1284.	1.0	13
71	Variable computed tomography appearances of COVID-19. Singapore Medical Journal, 2020, 61, 387-391.	0.3	12
72	Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study. Journal of Thrombosis and Thrombolysis, 2022, 53, 646-662.	1.0	11

#	Article	IF	CITATIONS
73	Influenza vaccine failure in the tropics: a retrospective cohort study of waning effectiveness. Epidemiology and Infection, 2020, 148, e299.	1.0	10
74	High-risk chest radiographic features associated with COVID-19 disease severity. PLoS ONE, 2021, 16, e0245518.	1.1	9
75	Postoperative <i>Mycoplasma hominis</i> brain abscess: keep it in mind!. BMJ Case Reports, 2017, 2017, bcr2016218022.	0.2	9
76	Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team. International Journal of Antimicrobial Agents, 2017, 50, 166-170.	1.1	8
77	Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and metaâ€analysis. Influenza and Other Respiratory Viruses, 2020, 14, 226-236.	1.5	8
78	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. Frontiers in Immunology, 2021, 12, 710217.	2.2	8
79	Influenza on cruise ships. Journal of Travel Medicine, 2018, 25, .	1.4	7
80	Finger stick blood test to assess postvaccination <scp>SARSâ€CoV</scp> â€2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 2022, 7, .	3.9	7
81	Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster Randomized Trial of Computerized Decision Support System and Prospective Review and Feedback. Open Forum Infectious Diseases, 2020, 7, ofaa254.	0.4	5
82	A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. Frontiers in Immunology, 2021, 12, 674279.	2.2	5
83	The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials, 2017, 18, 67.	0.7	4
84	Lack of latent tuberculosis (TB) screening and delay in anti-retroviral therapy initiation in HIV-TB co-infection: an 11-year study in an intermediate TB-burden country. International Journal of Infectious Diseases, 2021, 113, 178-183.	1.5	4
85	External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. Clinical Microbiology and Infection, 2022, 28, 884.e1-884.e3.	2.8	4
86	Sustaining Antimicrobial Stewardship in a High–Antibiotic Resistance Setting. JAMA Network Open, 2022, 5, e2210180.	2.8	4
87	The Uncertain Benefits of Combination Therapy for <i>Clostridium difficile</i> Infection. Clinical Infectious Diseases, 2016, 62, 809.1-810.	2.9	3
88	The absolute lymphocyte count accurately estimates CD4 counts in HIVâ€infected adults with virologic suppression and immune reconstitution. Journal of the International AIDS Society, 2014, 17, 19680.	1.2	2
89	Derivation and validation of an accurate estimation of CD4 counts from the absolute lymphocyte count in virologically suppressed and immunologically reconstituted HIV infected adults. BMC Infectious Diseases, 2015, 15, 330.	1.3	2
90	Rapidly waning vaccine effectiveness for influenza: How often should we revaccinate?. Journal of Travel Medicine, 2019, 26, .	1.4	2

#	Article	IF	CITATIONS
91	Reply. Ophthalmology, 2020, 127, e104-e105.	2.5	2
92	Identifying COVID-19 cases in outpatient settings. Epidemiology and Infection, 2021, 149, e92.	1.0	1
93	Infectious disease trends among immunocompromised hosts. Singapore Medical Journal, 2012, 53, 223-9; quiz 230.	0.3	1
94	Progressive Multifocal Leukoencephalopathy with Immune Reconstitution Inflammatory Syndrome (PML-IRIS): two case reports of successful treatment with mefloquine and a review of the literature. Annals of the Academy of Medicine, Singapore, 2012, 41, 620-4.	0.2	1
95	What′s new in critical illness and injury science? Preventing surgical infections requires the right antibiotic for the right duration. International Journal of Critical Illness and Injury Science, 2012, 2, 55.	0.2	0
96	Improved outcomes from HIV/TB co-infection in Singapore following a switch to earlier anti-retroviral therapy. Journal of the International AIDS Society, 2014, 17, 19624.	1.2	0
97	186. Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster-Randomized Trial of a Clinical Decision Support System to Supplement Antibiotic Prospective Review and Feedback. Open Forum Infectious Diseases, 2018, 5, S82-S83.	0.4	0
98	Reply to Letter to Editor. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105881.	0.7	0